Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1876 to 1890 of 9085 results

  1. Safeguarding adults in care homes

    Awaiting development Reference number: GID-QS10147 Expected publication date: TBC

    Quality standard
    Awaiting development

  2. Supporting independent living and preventing isolation in adults of working age with social care needs

    Awaiting development Reference number: GID-QS10149 Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Tasimelteon for treating sleep disturbance associated with Smith-Magenis syndrome [TSID12191]

    Awaiting development Reference number: GID-TA11746 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Icotrokinra for treating moderate to severe plaque psoriasis in people 12 years and over [ID6579]

    In development Reference number: GID-TA11780 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Zasocitinib for treating moderate to severe plaque psoriasis [ID6700]

    Awaiting development Reference number: GID-TA11926 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning: early value assessment

    Awaiting development Reference number: GID-HTG10389 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  7. Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care

    Awaiting development Reference number: GID-QS10144 Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]

    Awaiting development Reference number: GID-TA10198 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Timrepigene emparvovec for treating choroideremia [ID3916]

    Awaiting development Reference number: GID-TA10787 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Botaretigene sparoparvovec for treating RPGR mutation-associated X-linked retinitis pigmentosa [ID6286]

    Awaiting development Reference number: GID-TA11332 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]

    Awaiting development Reference number: GID-TA11530 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]

    Awaiting development Reference number: GID-TA10519 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [TSID10214]

    Awaiting development Reference number: GID-TA11069 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]

    In development Reference number: GID-TA11071 Expected publication date: TBC

    Technology appraisal guidance
    In development